Markets:

Overview

News

Currencies

International

Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

58.39 +2.31 (+4.12%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Vaxcyte Stock Is Sliding After Hours ↗

April 17, 2023

Vaxcyte Inc (NASDAQ: PCVX) shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a

Via Benzinga

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

April 17, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

April 17, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

April 16, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Preview: Vaxcyte's Earnings ↗

February 24, 2023

Via Benzinga

Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 17, 2023

Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.

Via Benzinga

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

March 30, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Expert Ratings for Vaxcyte ↗

January 03, 2023

Via Benzinga

Why Shares of Vaxcyte Rose 110.7% This Week ↗

October 29, 2022

The company released early data for a promising pneumonia vaccine.

Via The Motley Fool

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 27, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

February 21, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 16, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Vaxcyte to Present at the SVB Securities Global Biopharma Conference

February 07, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

January 05, 2023

From Vaxcyte, Inc.

Via GlobeNewswire

This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst ↗

January 03, 2023

Via Benzinga

Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday ↗

January 03, 2023

Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022 ↗

December 16, 2022

Via Benzinga

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

November 07, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗

December 15, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 ↗

November 17, 2022

Upgrades

Via Benzinga

Vaxcyte to Present at Upcoming Investor Conferences

November 03, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Why Investors Are Suddenly Excited About Vaxcyte

October 31, 2022

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

Via MarketBeat

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 28, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday ↗

October 26, 2022

U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Vaxcyte Announces Pricing of $600 Million Public Offering

October 26, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday ↗

October 25, 2022

Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.

Via Benzinga

Avis Budget, Scholastic And Other Big Gainers From Monday ↗

October 25, 2022

U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

October 24, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Dow Rises 1.5%; Nasdaq Jumps Over 100 Points ↗

October 24, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.